Ketamine

Dissociative

Ketamine is a dissociative anaesthetic that blocks NMDA glutamate receptors, producing detachment from the body, altered perception, and pain relief. It is widely used in medicine, increasingly studied as a rapid-acting antidepressant, and also used recreationally as 'Special K'.

Also known as: Special K, K, Ket, Vitamin K, Ketalar, Kit Kat, Esketamine (derivative)

Written by Psymerge Editorial Team · Last updated June 4, 2026

Key facts

CategoryDissociative
OnsetInsufflated 5–15 min; oral 20–30 min
PeakAbout 20–45 minutes
Total duration1–2 hours (longer if taken orally)
After-effectsUnsteadiness and impaired coordination for a few hours

Overview

Ketamine is a dissociative anaesthetic first developed in the 1960s and used worldwide in human and veterinary medicine. Chemically and pharmacologically it differs from the classic psychedelics: rather than acting on serotonin 5-HT2A receptors, it primarily blocks NMDA glutamate receptors, producing a sense of detachment from the body and surroundings (dissociation) along with altered perception and pain relief.

At sub-anaesthetic doses, effects come on quickly and are relatively short-lived, ranging from a floaty, dreamlike state to, at higher doses, an intense dissociation sometimes described as a 'k-hole'. Ketamine has also become important in psychiatry: a single intravenous dose can produce rapid antidepressant effects (Zarate et al., 2006), and a derivative, esketamine, is approved in some countries for treatment-resistant depression.

Unlike the classic psychedelics, ketamine carries a meaningful risk of dependence and, with heavy long-term use, can cause serious bladder and urinary-tract damage. This page summarises its pharmacology, effects, risks, and harm-reduction practices, drawing on peer-reviewed literature and established harm-reduction resources.

History & origins

Ketamine was first synthesised in 1962 by the chemist Calvin Stevens and developed as a safer alternative to the anaesthetic phencyclidine (PCP). Introduced into medical use around 1970, it became valued as an anaesthetic that largely preserves breathing and blood pressure, and it remains on the World Health Organization's list of essential medicines, widely used in emergency and veterinary settings.

From the 1970s onward ketamine was also used recreationally for its dissociative effects, becoming known as 'Special K' in club and party scenes. Since the 2000s it has drawn major scientific interest in psychiatry after research showed that a single low dose can rapidly reduce symptoms of treatment-resistant depression (Zarate et al., 2006); a related compound, esketamine, has since been approved in some countries for depression.

Pharmacology & how it works

Ketamine's main action is as an antagonist (blocker) of NMDA glutamate receptors in the brain, which underlies both its anaesthetic and dissociative effects. It also influences other systems, including opioid and monoaminergic signalling, and its rapid antidepressant effects are thought to involve downstream changes in glutamate signalling and synaptic plasticity (Zarate et al., 2006). This NMDA mechanism sets ketamine apart from the serotonergic classic psychedelics.

Chemical class
Arylcyclohexylamine; dissociative anaesthetic
Routes of administration
Insufflated (snorted), Oral, Intramuscular or intravenous (medical), Sublingual
Tolerance
Tolerance develops with repeated use and can escalate quickly in frequent users, contributing to dependence — a notable contrast with the classic psychedelics.

Pharmacokinetics

Onset and duration depend strongly on the route. Snorted, effects begin within about 5–15 minutes, peak at roughly 20–45 minutes, and largely resolve within 1–2 hours; oral use is slower and longer-lasting. Ketamine is a mixture of two mirror-image molecules, one of which — esketamine — is used as a separate medicine.

Effects

Physical Effects

  • Numbness and reduced sensitivity to pain (analgesia)
  • Loss of coordination and unsteadiness
  • Increased heart rate and blood pressure
  • Slurred speech
  • Nausea and vomiting
  • Dizziness

Psychological Effects

  • Dissociation: a sense of detachment from the body and surroundings
  • Distorted perception of time, space, and sensation
  • Dreamlike or 'floaty' states
  • Euphoria and relaxation
  • Intense immersive dissociation at high doses (the 'k-hole')
  • Confusion, anxiety, or disorientation

Spiritual Effects

  • Out-of-body or near-death-like experiences at high doses
  • Feelings of profound detachment or transcendence

Dosage Information

Low: 20–50 mg (insufflated, recreational)
Medium: 50–100 mg (insufflated, recreational)
High: 100–150+ (approaching the dissociative 'k-hole') mg (insufflated, recreational)

Doses depend heavily on route: oral doses are higher, and intravenous or intramuscular medical doses are calculated by body weight. The purity of street ketamine varies and look-alike dissociatives exist, so test before use, start low, and avoid redosing. Educational only and not an endorsement of use.

Risks & safety

Contraindications

Ketamine raises heart rate and blood pressure and strongly impairs coordination and awareness, so it is generally not advised for several groups:

  • Cardiovascular conditions: significant heart disease or uncontrolled high blood pressure.
  • Psychiatric history: a personal or family history of psychosis, which dissociatives can worsen.
  • Bladder or urinary-tract problems: ketamine can damage the urinary system (see serious risks).
  • Use of other sedatives: alcohol, benzodiazepines, or opioids (see interactions below).
  • Pregnancy, for which recreational safety has not been established.

Drug interactions

The most dangerous ketamine combinations involve other substances that depress the central nervous system or sedate the body.

  • Alcohol, benzodiazepines, opioids, and GHB/GBL: combining ketamine with these can cause heavy sedation, vomiting, loss of consciousness, and dangerous slowing of breathing.
  • Stimulants (including cocaine and amphetamines): add cardiovascular strain.
  • Other depressants or anaesthetics: additive effects increase the risk of accidents and airway problems.

This list is not exhaustive. Always check an up-to-date interaction resource and consult a clinician about any prescription medication (NIDA; TripSit drug-combination data).

Psychological distress & bad trips

Ketamine can cause acute anxiety, confusion, disorientation, and frightening dissociative experiences, particularly at higher doses or in unfamiliar settings. Because it strongly impairs coordination and awareness, distress can also arise from feeling unable to move or communicate. Heavy or frequent use has been linked to low mood, memory problems, and difficulties with thinking that may persist between sessions.

Rare but serious risks

Ketamine carries several distinctive physical risks, especially with heavy or long-term use:

  • Bladder and urinary-tract damage (ketamine-induced uropathy): chronic use can cause a painful, ulcerative cystitis with urinary frequency, urgency, and bleeding, and in severe cases irreversible bladder shrinkage and kidney damage (Shahani et al., 2007).
  • Loss of consciousness and airway risk: high doses can cause immobility and vomiting, with a danger of choking, especially when combined with other sedatives.
  • Accidents and injury: profound loss of coordination and awareness makes falls and accidents more likely.
  • Abdominal pain ('k-cramps') and liver or biliary problems have been reported in heavy users.
  • Cardiovascular strain from raised heart rate and blood pressure.

Vulnerable populations

Some groups face higher risk and are generally advised to avoid recreational ketamine:

  • People with heart conditions or high blood pressure.
  • People with a personal or family history of psychosis.
  • People with bladder, urinary-tract, or liver problems.
  • People taking sedatives such as alcohol, benzodiazepines, or opioids.
  • Adolescents and young adults, and pregnant or breastfeeding people, for whom safety has not been established.

Dependency & addiction potential

Unlike the classic psychedelics, ketamine has a clear potential for psychological dependence. Tolerance builds quickly, and some people develop a pattern of frequent, escalating use that can be difficult to stop. Compulsive use is also closely linked to the bladder damage described above. People who use ketamine regularly and want to cut down may benefit from medical and psychological support.

Overdose

Ketamine alone has a relatively wide safety margin and rarely causes fatal respiratory failure on its own, but overdose and serious harm are still possible — especially when ketamine is combined with alcohol or other depressants, which can dangerously slow breathing. High doses can cause complete immobility, vomiting (with a risk of choking), and unconsciousness. If someone becomes unresponsive, is struggling to breathe, or vomits while sedated, place them on their side and seek emergency medical help immediately.

Harm Reduction

  • Test your substance with a reagent kit: products sold as ketamine are sometimes substituted with other, more dangerous dissociatives.
  • Never mix ketamine with alcohol, benzodiazepines, opioids, or GHB/GBL, as the combination can dangerously slow breathing.
  • Use while seated or lying down to avoid falls, and never use alone.
  • Start with a low dose and avoid redosing, since effects and impairment build quickly.
  • Stay sober enough to help others, and place anyone who becomes heavily sedated on their side to protect their airway.
  • Watch for bladder or urinary symptoms (pain, urgency, or blood in the urine) — these are warning signs to stop using and seek medical advice.
  • Take regular breaks: frequent use raises the risk of dependence and bladder damage.

Cultural & spiritual context

Ketamine has no traditional or Indigenous ceremonial history. Its cultural significance is medical and modern: a mainstay anaesthetic in operating rooms, emergency medicine, and veterinary practice; a dissociative 'club drug' from the late twentieth century; and, most recently, the centre of a fast-growing field of ketamine and esketamine clinics for depression and other mental-health conditions. This medical legitimacy sits alongside ongoing concern about recreational misuse and the rise of largely unregulated ketamine-therapy services.

Legal Status

Laws vary widely by country and change frequently, so we don't track legal status here to avoid showing outdated information.

Check current worldwide legal status on Psychedelic Alpha

Frequently asked questions

How long do ketamine's effects last?

It depends on the route. Snorted, effects usually begin within 5–15 minutes, peak around 20–45 minutes, and largely fade within 1–2 hours. Oral use comes on more slowly and lasts longer, and unsteadiness can linger for several hours.

Is ketamine addictive?

Yes. Unlike the classic psychedelics, ketamine has a real potential for psychological dependence. Tolerance builds quickly and some people develop compulsive, escalating use that is hard to stop — a pattern closely linked to bladder damage.

What is a 'k-hole'?

A 'k-hole' is an intense, immersive dissociation that can occur at high doses, often involving immobility, profound detachment from the body, and out-of-body or dreamlike experiences. It can be frightening and leaves the person highly vulnerable.

Can ketamine damage your bladder?

Yes. Heavy, long-term use can cause ketamine-induced uropathy — a painful ulcerative cystitis with urinary urgency, frequency, and bleeding, and in severe cases lasting bladder and kidney damage (Shahani et al., 2007). Urinary pain or blood are warning signs to stop and seek medical help.

Is it dangerous to mix ketamine with alcohol?

Yes. Ketamine and alcohol are both central-nervous-system depressants, and combining them increases sedation, vomiting, and the risk of dangerously slowed breathing and choking. The same applies to benzodiazepines, opioids, and GHB/GBL.

Need Integration Support?

Connect with qualified integration guides who can help you process and integrate your experiences safely and effectively.

Find a Guide

Related substances

2C-B

Psychedelic

2C-B is a synthetic psychedelic phenethylamine first made by Alexander Shulgin and structurally related to mescaline. It is strongly dose-dependent: lower doses feel warm, sensual, and entactogen-like (similar to MDMA), while higher doses are clearly psychedelic, with effects lasting about 4–8 hours.

3-MMC

Synthetic

3-MMC (3-methylmethcathinone) is a synthetic cathinone and 'research chemical' closely related to mephedrone. It is a short-acting stimulant with mild entactogenic effects, a strong tendency to drive compulsive redosing, and significant risks including cardiovascular toxicity and dependence.

4-AcO-DMT

Psychedelic

4-AcO-DMT (psilacetin, O-acetylpsilocin) is a synthetic tryptamine that acts as a prodrug for psilocin — the same active compound produced by magic mushrooms. Its effects are widely reported to be very similar to psilocybin.

5-MeO-DMT

Psychedelic

5-MeO-DMT is an extremely potent, fast-acting psychedelic tryptamine found in the venom of the Sonoran Desert toad and in some plants, and also made synthetically. Rather than the rich visuals of DMT, it tends to produce a sudden, overwhelming experience of ego dissolution and oneness lasting only minutes.

References & further reading

  • Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., et al. (2006). A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression. Archives of General Psychiatry, 63(8), 856–864. https://doi.org/10.1001/archpsyc.63.8.856
  • Shahani, R., Streutker, C., Dickson, B., & Stewart, R. J. (2007). Ketamine-associated ulcerative cystitis: a new clinical entity. Urology, 69(5), 810–812. https://doi.org/10.1016/j.urology.2007.01.038
  • Grob, C. S., & Grigsby, J. (Eds.). (2021). Handbook of Medical Hallucinogens. New York: The Guilford Press.
  • National Institute on Drug Abuse (NIDA). Psychedelic and Dissociative Drugs. https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs
  • European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug profiles. https://www.emcdda.europa.eu/publications/drug-profiles_en
  • DanceSafe. Ketamine. https://dancesafe.org/drug-information/
  • Erowid. Ketamine Vault. https://www.erowid.org/chemicals/ketamine/
  • TripSit. Drug combinations chart. https://wiki.tripsit.me/wiki/Drug_combinations

About this article

Written by:
PE
Psymerge Editorial Team
Last updated June 4, 2026